Press release
Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders
LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 11,013,785 (\"the '785 patent\"). The '785 patent is a composition of matter patent directed to novel therapeutic proteins, including KER-050. The '785 patent contains 20 claims and expires no earlier than November 2037. “We are very pleased to have this foundational patent issued, which is the first for the Company’s wholly-owned internal programs and is a validation of the differentiated approach that we are taking to develop new product candidates,” said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros. “We will continue to strengthen our patent portfolio to support our discovery efforts and protect our expanding pipeline of wholly-owned assets for the treatment of hematological and musculoskeletal diseases.” Keros has an extensive intellectual property portfolio covering KER-050, KER-047 and KER-012, in addition to multiple preclinical assets in the Company’s pipeline. About KER-050 Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the TGF-β family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros’ lead protein therapeutic product candidate, KER-050, is being de...